| Title |
On the role of endothelin-converting enzyme-1 (ECE-1) and neprilysin in human breast cancer
|
|---|---|
| Published in |
Breast Cancer Research and Treatment, February 2007
|
| DOI | 10.1007/s10549-007-9516-9 |
| Pubmed ID | |
| Authors |
Martin Smollich, Martin Götte, George W. Yip, Eng-Siang Yong, Christian Kersting, Jeanett Fischgräbe, Isabel Radke, Ludwig Kiesel, Pia Wülfing |
| Abstract |
Endothelin-1 (ET-1) and its receptors, ET(A)R and ET(B)R, are overexpressed in breast carcinomas. However, little is known about the relevance of endothelin-converting enzyme-1 (ECE-1) and ET-1 degrading neprilysin (NEP). In this study, expression of ECE-1 and NEP was determined in 600 breast cancer tissue samples by immunohistochemistry; staining results were correlated with clinicopathological parameters. For ECE-1 expression, we found a significant correlation with VEGF (P < 0.001) and ET(A)R expression (P = 0.048). While patients with ECE-1 overexpressing tumours had more frequent disease recurrence (P = 0.03), NEP overexpression correlated with improved disease-free survival (DFS) (P = 0.023) and less frequent metastasis (P = 0.046). Also, a decrease of NEP expression with malignant progression (G1-G3) was found. ECE-1 inhibition using the selective ECE-1 inhibitor RO 67-7447 in MCF-7 breast cancer cells led to a significantly decreased ET-1 expression and reduced cell invasiveness (54.3% of controls, P = 0.014). Our results indicate that overexpression of ECE-1 is associated with unfavourable outcome, whereas NEP positively influences survival. Thus, expression of ECE-1 and NEP may have prognostic relevance. Due to the anti-invasive effect of the selective ECE-1 inhibitor, targeting ECE-1 may represent an innovative option in future breast cancer therapy. |
Mendeley readers
The data shown below were compiled from readership statistics for 32 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| China | 1 | 3% |
| Unknown | 31 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 9 | 28% |
| Student > Bachelor | 5 | 16% |
| Student > Postgraduate | 4 | 13% |
| Student > Master | 3 | 9% |
| Student > Doctoral Student | 2 | 6% |
| Other | 6 | 19% |
| Unknown | 3 | 9% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 7 | 22% |
| Biochemistry, Genetics and Molecular Biology | 6 | 19% |
| Medicine and Dentistry | 5 | 16% |
| Chemistry | 4 | 13% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 9% |
| Other | 3 | 9% |
| Unknown | 4 | 13% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 January 2023.
All research outputs
#4,886,859
of 23,509,253 outputs
Outputs from Breast Cancer Research and Treatment
#925
of 4,732 outputs
Outputs of similar age
#23,023
of 164,863 outputs
Outputs of similar age from Breast Cancer Research and Treatment
#7
of 37 outputs
Altmetric has tracked 23,509,253 research outputs across all sources so far. Compared to these this one has done well and is in the 76th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,732 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.2. This one has gotten more attention than average, scoring higher than 74% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 164,863 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 79% of its contemporaries.
We're also able to compare this research output to 37 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 59% of its contemporaries.